34.24USD+0.59%Mkt Cap: 2.47B USDP/E: —Last update: 2026-05-26
Vera Therapeutics, Inc., a clinical stage biotechnology company, focuses on the development and commercialization of transformative treatments for patients with immunological diseases. The company offers atacicept, a ful…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
105.81BDKKP/E 20.4
66.47BUSDP/E 15.5
46.56BEURP/E 30.5
43.89BEURP/E 36.5
39.41BUSDP/E 74.0
32.84BUSD—
32.05BSEKP/E 47.4
Indicators:|
Key Statistics
Company
Market Cap2.47B USD
Enterprise Value1.95B USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-299.62M USD
Revenue/Share—
Last Price34.24 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees339
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-9.70
PEG—
EV/EBITDA-5.08
EV/Revenue—
P/S—
P/B4.93
EPS (TTM)-5.54
EPS (Forward)-3.54
52W Range
18.7642% of range56.05
52W High56.05 USD
52W Low18.76 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-49.56%
ROA-40.78%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-241.10M USD
CapEx (TTM)630.00K USD
FCF Margin—
FCF Yield-7.27%
Net Debt-519.87M USD
Net Debt/EBITDA1.36
Balance Sheet
Debt/Equity0.13
Current Ratio13.64
Quick Ratio13.30
Book Value/Sh6.966 USD
Cash/Share8.313 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.2 (Strong Buy)
Target (Mean)78.00 USD
Target Range35.00 USD – 110.00 USD
# Analysts14
Ownership
Shares Out.71.78M
Float52.01M
Insiders0.88%
Institutions111.12%
Short Interest
Short Ratio7.8d
Short % Float14.90%
Short % Out.13.09%
Shares Short9.39M
Short (prev mo.)9.76M
Technical
SMA 5038.93 (-12.1%)
SMA 20036.03 (-5.0%)
Beta0.95
S&P 52W Chg28.31%
Avg Vol (30d)997.86K
Avg Vol (10d)1.01M
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—